×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Spain Active Pharmaceutical Ingredient Cancer Market

ID: MRFR/Pharma/49250-HCR
200 Pages
Garvit Vyas
October 2025

Spain Active Pharmaceutical Ingredient for Cancer Market Research Report: Size, Share, Trend Analysis By Types (Small Molecules, Biologics, Monoclonal Antibodies, Vaccines), By Applications (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer), By Manufacturing Process (Chemical Synthesis, Biotechnology, Extraction), andBy Formulation (Tablets, Injectables, Oral Solutions, Topical) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Spain Active Pharmaceutical Ingredient Cancer Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Spain Active Pharmaceutical Ingredient Cancer Market Summary

As per analysis, the Spain Active Pharmaceutical Ingredient For Cancer Market is projected to grow from USD 1.14 Billion in 2025 to USD 1.7 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.07% during the forecast period (2025 - 2035).

Key Market Trends & Highlights

The Spain Active Pharmaceutical Ingredient for Cancer Market is poised for growth driven by innovation and rising demand.

  • The chemotherapy segment remains the largest contributor to the market, reflecting a sustained reliance on traditional treatment methods.
  • Immunotherapy is emerging as the fastest-growing segment, indicating a shift towards more personalized treatment approaches.
  • Cytotoxic drugs continue to dominate the market, while targeted agents are rapidly gaining traction due to their efficacy.
  • Rising cancer incidence in Spain and government initiatives are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 1.1 (USD Billion)
2035 Market Size 1.7 (USD Billion)
CAGR (2025 - 2035) 4.07%

Major Players

Bristol-Myers Squibb (ES), Roche (ES), Novartis (ES), Pfizer (ES), Merck & Co. (ES), AstraZeneca (ES), Sanofi (ES), Teva Pharmaceutical Industries (ES), Bayer (ES)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Spain Active Pharmaceutical Ingredient Cancer Market Trends

The Spain Active Pharmaceutical Ingredient For Cancer Market is currently experiencing a dynamic evolution, driven by a combination of innovative research and regulatory advancements. The Spanish government has been actively promoting initiatives aimed at enhancing the development and accessibility of active pharmaceutical ingredients (APIs) specifically for cancer treatment. This focus aligns with the broader European Union strategies to improve healthcare outcomes and ensure that patients have access to the latest therapeutic options. Furthermore, collaborations between academic institutions and pharmaceutical companies in Spain are fostering a robust environment for research and development, which is likely to yield novel APIs tailored for various cancer types. In addition, the market appears to be influenced by increasing awareness of cancer prevention and treatment among the Spanish population. Public health campaigns and educational programs are contributing to a heightened demand for effective cancer therapies, which in turn drives the need for advanced APIs. The regulatory framework in Spain, characterized by stringent quality standards and safety protocols, seems to support the growth of this market by ensuring that only high-quality products reach healthcare providers and patients. Overall, the Spain Active Pharmaceutical Ingredient For Cancer Market is poised for continued growth, reflecting the nation's commitment to combating cancer through innovative pharmaceutical solutions.

Increased Investment in R&D

There is a noticeable trend towards increased investment in research and development within the Spain Active Pharmaceutical Ingredient For Cancer Market. This investment is primarily driven by both public and private sectors, aiming to foster innovation in cancer therapies. The collaboration between universities and pharmaceutical companies is particularly noteworthy, as it enhances the development of new APIs tailored to specific cancer types.

Regulatory Support for Innovation

The regulatory landscape in Spain appears to be increasingly supportive of innovation in the pharmaceutical sector. Recent initiatives by the Spanish Medicines Agency aim to streamline the approval process for new APIs, thereby encouraging the introduction of novel cancer treatments. This regulatory support is likely to enhance the market's attractiveness for both domestic and international pharmaceutical companies.

Growing Demand for Personalized Medicine

There is a rising trend towards personalized medicine within the Spain Active Pharmaceutical Ingredient For Cancer Market. As healthcare providers and patients seek more tailored treatment options, the demand for APIs that can be customized to individual patient profiles is expected to grow. This shift towards personalized approaches may lead to the development of more effective cancer therapies, aligning with the broader global movement towards precision medicine.

Spain Active Pharmaceutical Ingredient Cancer Market Drivers

Advancements in Biotechnology

Advancements in biotechnology are transforming the landscape of cancer treatment, significantly impacting the Spain Active Pharmaceutical Ingredient For Cancer Market. The emergence of biopharmaceuticals, including monoclonal antibodies and gene therapies, has revolutionized cancer care, offering targeted treatment options that improve patient outcomes. Spain has witnessed a surge in biopharmaceutical research, with numerous biotech firms focusing on developing innovative APIs for cancer therapies. This trend is supported by collaborations between academic institutions and industry players, fostering an environment conducive to innovation. As these advancements continue to evolve, the Spain Active Pharmaceutical Ingredient For Cancer Market is poised for growth, driven by the demand for cutting-edge biotechnological solutions in cancer treatment.

Rising Cancer Incidence in Spain

The increasing incidence of cancer in Spain is a primary driver for the Spain Active Pharmaceutical Ingredient For Cancer Market. According to the Spanish Society of Medical Oncology, cancer cases are projected to rise significantly, with estimates suggesting over 280,000 new cases annually by 2025. This alarming trend necessitates the development and production of effective active pharmaceutical ingredients (APIs) to combat various cancer types. As the population ages and lifestyle factors contribute to higher cancer rates, the demand for innovative treatments and therapies intensifies. Consequently, pharmaceutical companies are likely to invest more in the research and development of APIs tailored for cancer treatment, thereby propelling the growth of the Spain Active Pharmaceutical Ingredient For Cancer Market.

Increasing Focus on Generic Drugs

The growing emphasis on generic drugs is a significant driver for the Spain Active Pharmaceutical Ingredient For Cancer Market. As healthcare costs continue to rise, there is a pressing need for affordable cancer treatments. Generic APIs offer a cost-effective alternative to branded drugs, making them more accessible to patients. In Spain, the government has been promoting the use of generics to enhance healthcare affordability, which has led to an increase in the production and consumption of generic APIs for cancer treatment. This shift not only benefits patients but also encourages pharmaceutical companies to invest in the development of generic APIs, thereby stimulating the growth of the Spain Active Pharmaceutical Ingredient For Cancer Market.

Government Initiatives and Funding

Government initiatives aimed at enhancing cancer treatment capabilities are pivotal for the Spain Active Pharmaceutical Ingredient For Cancer Market. The Spanish government has implemented various funding programs to support cancer research and the development of new therapies. For instance, the National Cancer Strategy emphasizes the importance of improving cancer care and treatment options, which includes the promotion of innovative APIs. This strategic focus is expected to attract investments from both public and private sectors, fostering collaboration between research institutions and pharmaceutical companies. As a result, the Spain Active Pharmaceutical Ingredient For Cancer Market is likely to experience accelerated growth, driven by increased funding and support for cancer-related research initiatives.

Collaboration Between Industry and Academia

Collaboration between the pharmaceutical industry and academic institutions is emerging as a crucial driver for the Spain Active Pharmaceutical Ingredient For Cancer Market. These partnerships facilitate the exchange of knowledge and resources, leading to the development of innovative APIs for cancer therapies. Spanish universities and research centers are increasingly engaging with pharmaceutical companies to conduct joint research projects focused on cancer treatment. This collaborative approach not only accelerates the discovery of new APIs but also enhances the overall quality of cancer care in Spain. As these partnerships continue to flourish, the Spain Active Pharmaceutical Ingredient For Cancer Market is likely to benefit from a steady influx of innovative solutions and therapies.

Market Segment Insights

By Application: Chemotherapy (Largest) vs. Immunotherapy (Fastest-Growing)

In the Spain Active Pharmaceutical Ingredient for Cancer Market, the application segment is primarily dominated by Chemotherapy, which holds the largest market share due to its established usage and extensive evidence supporting its efficacy in treating various cancers. Following Chemotherapy, Targeted Therapy and Hormonal Therapy occupy a significant position, with Targeted Therapy rapidly gaining traction as more personalized treatment options become available. Immunotherapy, although a smaller segment presently, is capturing attention with its novel approaches to treating cancer and its growing acceptance among clinicians and patients alike. Growth trends within this segment are largely driven by innovations in drug development and an increasing focus on personalized medicine. The shift towards more targeted and effective treatment options is propelling the popularity of Targeted Therapy and Immunotherapy, as they promise improved outcomes with potentially fewer side effects. Moreover, rising cancer incidences in Spain and ongoing research investments into new treatment modalities are significant factors pushing the market forward. The demand for improved health care solutions is highlighted through the increasing adoption of these therapies in clinical practices.

Chemotherapy: Dominant vs. Immunotherapy: Emerging

Chemotherapy remains the dominant application in the Spain Active Pharmaceutical Ingredient for Cancer Market, known for its broad utilization in cancer treatment protocols and a history of well-established regimens. Its wide acceptance is coupled with extensive research backing, making it a go-to choice for various cancers. Immunotherapy, on the other hand, is emerging as a revolutionary approach that harnesses the body’s immune system to combat cancer. Though currently less prevalent, Immunotherapy is experiencing rapid growth, bolstered by clinical successes and an expanding range of FDA-approved therapies. As awareness increases around the potential benefits and lower toxicity profiles of immunotherapies compared to traditional chemotherapeutic agents, their market position strengthens significantly.

By Drug Type: Cytotoxic Drugs (Largest) vs. Targeted Agents (Fastest-Growing)

In the Spain Active Pharmaceutical Ingredient for Cancer Market, the drug type segment is primarily dominated by Cytotoxic Drugs, which hold a significant market share due to their established use in chemotherapy. These drugs are effective against a wide range of malignancies and are widely employed in treatment protocols. On the other hand, Targeted Agents are gaining traction, gradually increasing their market share through innovative therapies designed to target specific cancer cell pathways, thus minimizing damage to healthy cells. Growth trends in this segment are heavily influenced by advancements in cancer research and a growing emphasis on personalized medicine. The rise of biologics and hormonal agents is noteworthy as they provide alternative treatment options that can improve patient outcomes. The increasing incidence of cancer, coupled with the introduction of novel therapeutics and drug combinations, is likely to drive the demand further for these drug types, especially targeted therapies that are seen as the future of cancer treatment.

Cytotoxic Drugs (Dominant) vs. Biologics (Emerging)

Cytotoxic Drugs have long been the cornerstone of cancer treatment, renowned for their aggressive approach in combating rapidly dividing cells. Their well-established efficacy has cemented their position in therapeutic regimens. However, as the medical landscape evolves, Biologics are emerging, driven by their ability to specifically target cancer cells with minimal side effects compared to traditional chemotherapy. These agents, often derived from living organisms, offer a newer avenue for treatment that aligns with personalized medicine trends. With regulatory support and a heightened focus on innovative treatments, Biologics are rapidly gaining ground and are poised to transform patient care in oncology, particularly in the Spain market.

By Formulation Type: Injectable (Largest) vs. Oral (Fastest-Growing)

In the Spain Active Pharmaceutical Ingredient for Cancer market, the formulation types exhibit distinctive market share distributions. Injectable formulations dominate the landscape, benefiting from their widespread use in hospitals and cancer treatment centers due to their rapid action and effectiveness. Oral formulations, while currently a smaller segment, are gaining traction among patients who prefer non-invasive treatment options, which reflects a growing trend toward patient comfort and ease of administration. Growth trends in this segment highlight a significant shift towards oral formulations, propelled by innovations in drug delivery and patient-friendly designs. The increasing preference for at-home care solutions and advancements in oral chemotherapy options are driving this growth. Injectable formulations continue to be relevant due to their proven efficacy, but the expansion of oral therapies showcases a critical evolution in treatment methodologies for cancer care in Spain.

Injectable (Dominant) vs. Oral (Emerging)

Injectable formulations are the dominant players in the cancer treatment sector due to their immediate bioavailability and efficacy. They are often preferred for various chemotherapy drugs, where rapid action is critical. Their presence in hospitals is significant, as medical professionals frequently administer these medications. On the other hand, oral formulations represent an emerging segment, appealing to a growing demographic of patients seeking more convenient treatment options. These formulations have seen innovation in taste masking and pill design, making them easier to consume. The appeal of oral medication lies in enhanced patient compliance and quality of life, positioning them as a viable alternative that may reshape the future landscape of cancer therapeutics in Spain.

By Route of Administration: Intravenous (Largest) vs. Oral (Fastest-Growing)

In the Spain Active Pharmaceutical Ingredient For Cancer Market, the route of administration plays a critical role in treatment strategies. The intravenous (IV) route holds the dominant market share, preferred for its rapid absorption and effectiveness for acute conditions. Following IV, the oral route is gaining traction due to its convenience and non-invasive nature, appealing to a significant portion of patients. Meanwhile, subcutaneous and intramuscular routes occupy a smaller share, reflecting specific therapeutic needs and patient preferences.

Intravenous (Dominant) vs. Oral (Emerging)

The intravenous route remains the dominant choice for administering active pharmaceutical ingredients for cancer treatment in Spain. This preference stems from its ability to deliver drugs directly into the bloodstream, ensuring immediate therapeutic effect and allowing for precise dosage adjustments. Conversely, the oral route is rapidly emerging as a viable alternative, driven by advancements in drug formulation and patient-centered care. Oral formulations are favored for their ease of use and better adherence in outpatient settings, appealing particularly to those seeking a less invasive treatment experience. As pharmaceutical companies innovate, both routes will likely continue to evolve, balancing efficacy with patient comfort.

By Patient Demographics: Adult (Largest) vs. Geriatric (Fastest-Growing)

In the Spain Active Pharmaceutical Ingredient for Cancer Market, the demographics segment reveals a significant distribution, with adults holding the largest share. This group includes individuals aged 18 and older, who are the primary consumers of cancer therapies due to the higher incidence of cancer diagnoses within this age range. Geriatric patients, while smaller in number compared to adults, are rapidly gaining importance as the population ages, leading to a surge in therapeutic needs in this age category. Market growth within the patient demographics segment is influenced by changing healthcare policies and an increasing focus on personalized medicine. The Geriatric segment is emerging as the fastest-growing demographic, driven by the elderly population's rising prevalence of cancer and the necessity for specialized treatments that cater to their unique health profiles. This trend encourages pharmaceutical companies to innovate and develop more precise APIs that address the complex health requirements of older patients.

Adult (Dominant) vs. Pediatric (Emerging)

In the context of the Spain Active Pharmaceutical Ingredient for Cancer Market, adults represent the dominant demographic, primarily due to the higher prevalence of cancer among this age group. Adults often experience various types of cancers, necessitating an extensive range of pharmaceutical interventions. Conversely, the pediatric segment, although still emerging, is witnessing increasing recognition by healthcare stakeholders. The rise in childhood cancer cases and enhanced awareness about pediatric oncology has led to more focused research and development activities. This emerging segment is characterized by a growing pipeline of age-appropriate dosage forms and specialized APIs, which cater specifically to younger patients. As pediatric oncology advances, its importance in treatment strategies is set to grow, prompting pharmaceutical companies to tailor their products accordingly.

Get more detailed insights about Spain Active Pharmaceutical Ingredient Cancer Market
Request Free Sample

Key Players and Competitive Insights

The Active Pharmaceutical Ingredient for Cancer market in Spain is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on localized production. Major players such as Bristol-Myers Squibb (ES), Roche (ES), and Novartis (ES) are actively shaping the market through their distinct operational strategies. Bristol-Myers Squibb (ES) emphasizes research and development, particularly in immuno-oncology, which appears to be a focal point for enhancing their product pipeline. Roche (ES) is leveraging its strong position in diagnostics to integrate personalized medicine into its therapeutic offerings, while Novartis (ES) is pursuing aggressive expansion in biologics, indicating a shift towards more complex and targeted therapies. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and patient-centric solutions.

Key business tactics within this market include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness. The competitive structure is moderately fragmented, with several key players exerting influence over market dynamics. This fragmentation allows for a variety of approaches to market entry and product development, fostering a landscape where innovation can thrive alongside established practices.

In December 2025, Roche (ES) announced a strategic partnership with a leading biotechnology firm to co-develop a novel active pharmaceutical ingredient aimed at enhancing the efficacy of existing cancer therapies. This collaboration is expected to leverage Roche's extensive research capabilities and the biotech firm's innovative technology, potentially leading to breakthroughs in treatment options. The strategic importance of this partnership lies in its potential to accelerate the development of new therapies, thereby reinforcing Roche's competitive edge in the market.

In November 2025, Novartis (ES) launched a new manufacturing facility in Spain dedicated to the production of advanced biologics for cancer treatment. This facility is expected to enhance local supply capabilities and reduce lead times for critical therapies. The establishment of this facility underscores Novartis's commitment to regional production and its strategy to meet the growing demand for biologics, which are increasingly becoming a cornerstone of cancer treatment.

In January 2026, AstraZeneca (ES) unveiled a digital platform designed to streamline the supply chain for its active pharmaceutical ingredients. This initiative aims to enhance transparency and efficiency, allowing for real-time tracking of production and distribution processes. The strategic significance of this digital transformation lies in its potential to improve operational efficiency and reduce costs, positioning AstraZeneca favorably in a competitive landscape that increasingly values technological integration.

As of January 2026, current trends in the Active Pharmaceutical Ingredient for Cancer market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the need to collaborate in order to innovate and respond to market demands effectively. The competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these aspects will be better positioned to thrive in an increasingly complex and competitive environment.

Key Companies in the Spain Active Pharmaceutical Ingredient Cancer Market include

Industry Developments

In recent months, the Spain Active Pharmaceutical Ingredient for Cancer Market has seen notable developments, particularly with key companies that play a significant role in this sector. Pfizer and Merck have been active in Research and Development efforts aimed at enhancing existing cancer therapies, which is bolstered by government initiatives to promote biotechnology investments in Spain.

There have also been reports of AstraZeneca expanding its production capabilities in Spain to meet the rising demand for oncology drugs, reflecting the market's continuous growth. In terms of mergers and acquisitions, Sanofi announced in April 2023 its acquisition of a local biotech firm focusing on novel cancer treatments, enhancing its portfolio in the oncology sector.

Furthermore, Novartis has increased its presence in Spain by forming a strategic partnership with a leading pharmaceutical distributor, which is expected to improve access to cancer treatment APIs across the country.

The Spanish government's commitment to strengthen the pharmaceutical industry through investments and support for startups appears to significantly affect the market landscape, fostering a conducive environment for expansion and innovation in cancer treatments. The active collaboration amongst major players is indicative of an increasingly competitive market landscape in Spain's battle against cancer.

Future Outlook

Spain Active Pharmaceutical Ingredient Cancer Market Future Outlook

The Active Pharmaceutical Ingredient for Cancer Market in Spain is projected to grow at a 4.07% CAGR from 2025 to 2035, driven by increasing cancer prevalence, technological advancements, and regulatory support.

New opportunities lie in:

  • Development of targeted therapies utilizing novel APIs
  • Expansion of biosimilar production capabilities
  • Investment in AI-driven drug discovery platforms

By 2035, the market is expected to be robust, driven by innovation and strategic investments.

Market Segmentation

Spain Active Pharmaceutical Ingredient Cancer Market Drug Type Outlook

  • Cytotoxic Drugs
  • Hormonal Agents
  • Biologics
  • Targeted Agents

Spain Active Pharmaceutical Ingredient Cancer Market Application Outlook

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy

Spain Active Pharmaceutical Ingredient Cancer Market Formulation Type Outlook

  • Injectable
  • Oral
  • Topical
  • Intravenous

Spain Active Pharmaceutical Ingredient Cancer Market Patient Demographics Outlook

  • Adult
  • Pediatric
  • Geriatric
  • Gender Specific

Spain Active Pharmaceutical Ingredient Cancer Market Route of Administration Outlook

  • Intravenous
  • Oral
  • Subcutaneous
  • Intramuscular

Report Scope

MARKET SIZE 20241.1(USD Billion)
MARKET SIZE 20251.14(USD Billion)
MARKET SIZE 20351.7(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)4.07% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledBristol-Myers Squibb (ES), Roche (ES), Novartis (ES), Pfizer (ES), Merck & Co. (ES), AstraZeneca (ES), Sanofi (ES), Teva Pharmaceutical Industries (ES), Bayer (ES)
Segments CoveredApplication, Drug Type, Formulation Type, Route of Administration, Patient Demographics
Key Market OpportunitiesGrowing demand for innovative therapies drives expansion in the Spain Active Pharmaceutical Ingredient For Cancer Market.
Key Market DynamicsRising demand for innovative Active Pharmaceutical Ingredients drives competition and regulatory scrutiny in Spain's cancer treatment sector.
Countries CoveredSpain
Leave a Comment

FAQs

What is the current valuation of the Spain Active Pharmaceutical Ingredient for Cancer Market?

The market valuation was 1.1 USD Billion in 2024.

What is the projected market size for the Spain Active Pharmaceutical Ingredient for Cancer Market by 2035?

The market is projected to reach 1.7 USD Billion by 2035.

What is the expected CAGR for the Spain Active Pharmaceutical Ingredient for Cancer Market during the forecast period?

The expected CAGR from 2025 to 2035 is 4.07%.

Which companies are the key players in the Spain Active Pharmaceutical Ingredient for Cancer Market?

Key players include Bristol-Myers Squibb, Roche, Novartis, Pfizer, Merck & Co., AstraZeneca, Sanofi, Teva Pharmaceutical Industries, and Bayer.

How does the market segment by application look in terms of valuation?

In 2024, chemotherapy was valued at 0.4 USD Billion, while targeted therapy was at 0.3 USD Billion.

What are the projected valuations for the drug type segment in the Spain Active Pharmaceutical Ingredient for Cancer Market?

Cytotoxic drugs were valued at 0.44 USD Billion in 2024, with projections indicating growth to 0.66 USD Billion.

What is the valuation of the oral formulation type in the market?

The oral formulation type was valued at 0.5 USD Billion in 2024, with expectations of reaching 0.7 USD Billion.

What does the route of administration segment reveal about intravenous drugs?

Intravenous drugs were valued at 0.4 USD Billion in 2024, with projections suggesting an increase to 0.6 USD Billion.

How does the market segment by patient demographics appear?

In 2024, the adult demographic was valued at 0.55 USD Billion, indicating a strong market presence.

What is the expected growth trend for hormonal agents in the Spain Active Pharmaceutical Ingredient for Cancer Market?

Hormonal agents were valued at 0.22 USD Billion in 2024, with projections indicating growth to 0.33 USD Billion.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓